Unknown PHASE2 INTERVENTIONAL 2-arm NCT01788176

The Use of Zoledronic Acid to Complex Regional Pain Syndrome (Aclasta)

Phase 2 Study - The Use of a Single 5 mg Dose of Zoledronic Acid in Complex Regional Pain Syndrome Patient.

Sponsor: Novartis

Conditions Complex Regional Pain Syndromes

Updated 6 times since 2017 Last updated: Feb 8, 2013 Started: Dec 31, 2013 Primary completion: Dec 31, 2015 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01788176, this PHASE2 trial focuses on Complex Regional Pain Syndromes and remains ongoing. Sponsored by Novartis, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
University of Sao Paulo General Hospital

Data source: University of Sao Paulo General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil